A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

Official title: A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

Summary: This is a single-arm, open-label clinical study to evaluate the safety, tolerability and preliminary efficacy of IX001 TCR-T injection in advanced pancreatic cancer patients with KRAS G12V mutation.

Conditions: Pancreatic Cancer

Study type: INTERVENTIONAL

Primary purpose: TREATMENT

Phases: PHASE1

Enrollment: 9 (ESTIMATED)

Status: RECRUITING

Completion: 2027-09-27 (ESTIMATED)